Growth suppression of cervical carcinoma by pigment epithelium-derived factor via anti-angiogenesis

Yang, Jun; Chen, Shuqin; Huang, Xuan; Han, Jieun; Wang, Qingsong; Shi, Dingbo; Cheng, Rui; Gao, Guoquan; Yang, Xia

doi:10.4161/cbt.9.12.11635

Cited by 27 publications

(23 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Reduced PEDF expression is a potent promoter of tumor growth and angiogenesis in breast cancer (36), and the loss of PEDF enables melanoma cells to acquire an invasive phenotype (37). The results of the present study were concordant with previous findings in the majority of solid tumors (22,26,36,37), which suggested that PEDF may have an important role in the progression of PTC. However, certain observations of the current study, including the association of PEDF expression levels with tumor stage and its lack of association with multifocality, must be investigated in further studies with a larger cohort, as only 26 cases of a T3 tumor and 12 cases of multifocality were recruited for the present study.…”

Section: Discussionsupporting

confidence: 92%

“…For instance, PEDF was able to suppress angiogenesis in a gastric carcinoma xenograft model by down regulating HIF1α and VEGF expression (27). Furthermore, PEDF suppressed tumor growth in a cervical cancer cell line by down regulating the expression of VEGF and HIF1α, which demonstrated the anti-angiogenic activity of PEDF (26). In addition, the HIF1α and VEGF/PEDF signaling pathway is targeted in impacting nasopharyngeal carcinoma cell proliferation and angiogenesis (28).…”

Section: Discussionmentioning

confidence: 96%

“…The anti-angiogenic effect of PEDF is performed primarily through the disruption of microvascular network distribution (25)(26)(27)(28). Vascular endothelial growth factor (VEGF) is an established pro-angiogenic factor and numerous studies have reported an inverse correlation between PEDF and VEGF expression levels in certain tumor models (21,(25)(26)(27)(28).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Pigment epithelium-derived factor has a role in the progression of papillary thyroid carcinoma by affecting the HIF1α-VEGF signaling pathway

Sun

Shi

et al. 2016

Oncology Letters

View full text Add to dashboard Cite

Abstract. The progression mechanism of papillary thyroid carcinoma (PTC) remains largely unknown. Accumulating evidence has suggested that various targets of pigment epithelium-derived factor (PEDF) are able to inhibit cancer progression. The aim of the present study was to examine PEDF expression in PTC patients and to investigate its relationship with aggressive clinicopathological features, as well as to explore whether PEDF affects the progression of PTC via the hypoxia-inducible factor 1α (HIF1α)-vascular endothelial growth factor (VEGF) pathway. A total of 271 patients with PTC, including 24 men and 247 women, were enrolled in the present study. Relevant patient data, including demographic features, preoperative clinical features and pathological features, were collected for analysis. The protein expression levels of PEDF in PTC tissues were detected using immunohistochemical staining, and the mRNA expression levels of PEDF, VEGF and HIF1α in 15 PTC tissues with lymph node metastasis (LNM) and 10 tissues without LNM were detected using reverse transcription-quantitative polymerase chain reaction. Immunohistochemical staining with an anti-PEDF antibody detected PEDF expression in 74.5% of the PTC tissues. PEDF expression levels were significantly correlated with LNM, extrathyroid invasion, a high TNM stage, the presence of the BRAF V600E mutation and tumor size. PEDF mRNA expression levels were significantly decreased in PTC tissues with LNM, as compared with PTC tissues without LNM, while the mRNA expression levels of HIF1α and VEGF were markedly increased in PTC tissues with LNM. Taken together, the results of the present study suggested that PEDF plays a role in the progression of PTC, and that PEDF may exert an anti-angiogenesis role by affecting the HIF1α-VEGF pathway, eventually inhibiting the metastasis of PTC.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussionmentioning

confidence: 96%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Pigment epithelium-derived factor has a role in the progression of papillary thyroid carcinoma by affecting the HIF1α-VEGF signaling pathway

Sun

Shi

et al. 2016

Oncology Letters

View full text Add to dashboard Cite

show abstract

“…Purified recombinant PEDF and PEDF-based viral vectors have been investigated in a lot of studies. Nevertheless, a suboptimal half-life in plasma reduces their possible therapeutic effects (14,25). To overcome this shortcoming, a novel and more effective vehicle is needed.…”

Section: Discussionmentioning

confidence: 99%

“…It has been demonstrated that PEDF can inhibit the proliferation and migration of endothelial cells and can induce apoptosis (8). A number of studies showed inverse correlation between PEDF levels, grade and metastatic potential of prostate cancer (11), pancreatic cancer (12), glioma (13), cervical carcinoma (14) as well as lung carcinoma (15).…”

Section: Introductionmentioning

confidence: 99%

Therapeutic potential of bone marrow-derived mesenchymal stem cells producing pigment epithelium-derived factor in lung carcinoma

Chen

Cheng

Yin

et al. 2012

International Journal of Molecular Medicine

View full text Add to dashboard Cite

Abstract. Specific and efficient gene delivery to target cells and the subsequent expression of the RNA and protein is crucial to the success of gene-based therapy for cancer. Mesenchymal stem cells (MSCs) represent novel and efficient tools for delivery of therapeutic agents to tumor cells. In this study, we evaluated the potential of bone marrow-derived mesenchymal stem cells, genetically modified to express pigment epithelium-derived factor (PEDF) for the treatment of Lewis lung carcinoma (LLC). MSCs derived from murine bone marrow were efficiently engineered to express human PEDF by adenoviral transduction, and the expression and bioactivity of the transgenic protein from engineered MSCs were confirmed in vitro. Animal experiments showed that the systemic administration of MSCs treated with PEDF dramatically reduced the growth of LLC tumors and significantly prolonged survival. Immunohistochemistry analysis of the tumors from MSC-PEDF-treated animals indicated an increase in apoptosis and a decrease in microvessel density. ELISA showed that the group of MSCs treated with PEDF had relatively higher expression levels of PEDF in tumor tissue and lower levels in serum compared with the free Ad-PEDF group. These results suggest that MSCs have potential use as effective delivery of vehicles for therapeutic genes in the treatment of LLC.

show abstract

Directed Evolution Enables Simultaneous Controlled Release of Multiple Therapeutic Proteins from Biopolymer‐Based Hydrogels

Teal

Hettiaratchi

et al. 2022

Advanced Materials

View full text Add to dashboard Cite

With the advent of increasingly complex combination strategies of biologics, independent control over their delivery is the key to their efficacy; however, current approaches are hindered by the limited independent tunability of their release rates. To overcome these limitations, directed evolution is used to engineer highly specific, low affinity affibody binding partners to multiple therapeutic proteins to independently control protein release rates. As a proof‐of‐concept, specific affibody binding partners for two proteins with broad therapeutic utility: insulin‐like growth factor‐1 (IGF‐1) and pigment epithelium‐derived factor (PEDF) are identified. Protein–affibody binding interactions specific to these target proteins with equilibrium dissociation constants (KD) between 10−7 and 10−8 m are discovered. The affibodies are covalently bound to the backbone of crosslinked hydrogels using click chemistry, enabling sustained, independent, and simultaneous release of bioactive IGF‐1 and PEDF over 7 days. The system is tested with C57BL/6J mice in vivo, and the affibody‐controlled release of IGF‐1 results in sustained activity when compared to bolus IGF‐1 delivery. This work demonstrates a new, broadly applicable approach to tune the release of therapeutic proteins simultaneously and independently and thus the way for precise control over the delivery of multicomponent therapies is paved.

show abstract

Growth suppression of cervical carcinoma by pigment epithelium-derived factor via anti-angiogenesis

Cited by 27 publications

References 30 publications

Pigment epithelium-derived factor has a role in the progression of papillary thyroid carcinoma by affecting the HIF1α-VEGF signaling pathway

Pigment epithelium-derived factor has a role in the progression of papillary thyroid carcinoma by affecting the HIF1α-VEGF signaling pathway

Therapeutic potential of bone marrow-derived mesenchymal stem cells producing pigment epithelium-derived factor in lung carcinoma

Directed Evolution Enables Simultaneous Controlled Release of Multiple Therapeutic Proteins from Biopolymer‐Based Hydrogels

Contact Info

Product

Resources

About